We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$194M
Cap. Flow %
-10.46%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.69%
2 Healthcare 6.69%
3 Materials 0.25%
4 Financials 0.16%
5 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
126
CALL
DELISTED
Esperion Therapeutics
ESPR
$1.13M 0.06%
+320
New +$7.33K
EXEL icon
127
PUT
Exelixis
EXEL
$13.9B
$1.08M 0.06%
500
-4,892
-91% -$99.5K
ADYX
128
DELISTED
Adynxx Inc
ADYX
$1.08M 0.06%
35,518
+17,178
+94% +$609K
RDHL
129
Redhill Biopharma
RDHL
$3.54M
$1.04M 0.06%
108
-84
-44% -$839K
RDUS
130
DELISTED
Radius Health, Inc.
RDUS
$998K 0.05%
+25,828
New +$1.08M
CTSO icon
131
Cytosorbents Corp
CTSO
$19.6M
$990K 0.05%
+11,000
New +$1.23M
APDNW
132
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$985K 0.05%
2,431,089
+153,477
+7% +$69.8K
SPHS
133
DELISTED
Sophiris Bio, Inc.
SPHS
$972K 0.05%
343,422
-153,307
-31% -$420K
IMMU
134
CALL
DELISTED
Immunomedics Inc
IMMU
$969K 0.05%
+1,497
New +$7.58K
SCMP
135
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$935K 0.05%
85,000
+10,000
+13% +$116K
ESPR
136
PUT
DELISTED
Esperion Therapeutics
ESPR
$907K 0.05%
+257
New +$5.88K
ALDX icon
137
Aldeyra Therapeutics
ALDX
$82.6M
$898K 0.05%
+179,627
New +$925K
BLCM
138
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$895K 0.05%
+7,250
New +$950K
TOVX icon
139
Theriva Biologics
TOVX
$10.5M
$892K 0.05%
162
-185
-53% -$1.29M
ZGNX
140
CALL
DELISTED
Zogenix, Inc.
ZGNX
$885K 0.05%
816
-11,550
-93% -$117K
RXDX
141
DELISTED
Ignyta, Inc.
RXDX
$825K 0.04%
95,918
-99,082
-51% -$724K
CORV
142
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$819K 0.04%
273,010
-164,710
-38% -$486K
VTVT icon
143
vTv Therapeutics
VTVT
$120M
$811K 0.04%
3,095
-219
-7% -$49.9K
TPST icon
144
Tempest Therapeutics
TPST
$12.7M
$792K 0.04%
145
+128
+753% +$596K
CAPR icon
145
Capricor Therapeutics
CAPR
$494M
$791K 0.04%
23,759
-13,446
-36% -$373K
ADVM
146
DELISTED
Adverum Biotechnologies
ADVM
$763K 0.04%
28,263
-68
-0.2% -$1.93K
ONSIW
147
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$763K 0.04%
930,592
– –
CBMXW
148
DELISTED
CombiMatrix Corporation Warrant
CBMXW
$762K 0.04%
619,750
-225,167
-27% -$201K
CYTXW
149
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$757K 0.04%
1,261,647
-12,065
-0.9% -$8.5K
SINT icon
150
SiNtx Technologies
SINT
$11.3M
– –
0
– –
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $194M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 81% a quarter earlier, followed by Healthcare and Materials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.